Tenascin-C orchestrates radiotherapy-induced head and neck tumor regression

Read full text
Authors: Thomas Loustau, Ioanna Mitrentsi, Nuohan Wang, Caroline Spenlé, Alexia Pavlidaki, Thibaud Tranchant, Gilles Riegel, Akhil Venu, Rime Oueidat, Manuel Koch, Marion Dumas, Fanny Wack
+19 more Aurélie Hirschler, Christine Carapito, Nicodème Paul, Raphaël Carapito, Matthias Mörgelin, Uwe J. Hansen, Joyce Azzi, Lucie Aubergeon, Nathalie Salomé, Sayda Dhaouadi, Pierre Grenot, Balkiss Bouhaouala-Zahar, Simona Y. La Cioppa, Philippe Oertle, Valerio Izzi, Marija Plodinec, Georges Noël, Hélène Burckel, Gertraud Orend
Cited by: 1
References: 62

Abstract

Given that head and neck squamous cell carcinoma (HNSCC) patients have poor survival outcomes, a better understanding of the therapeutic benefits of ionizing irradiation (IR), the major treatment modality besides surgery, is needed. A confounding factor is the immunosuppressive tumor microenvironment determined by tenascin-C (TNC), a highly abundant extracellular matrix molecule upregulated by IR. We investigated the roles of TNC on radio-induced tumor regression in a murine oral HNSCC model expressing or lacking TNC. While tumors in a TNC-expressing host were radiosensitive, they were radioresistant in TNC genetically depleted mice. We identified fibroblast reticular cells (FRCs) as critical regulators. TNC plays a compartmentalized and dual role in regulating tumor radiosensitivity with a detrimental role in the tumor stroma opposed to an essential role in the tumor-draining lymph nodes. This is relevant as a high FRC signature and high TNC levels together correlate with shorter HNSCC patient survival. TNC-expressing FRCs may be an excellent novel target to improve radiotherapy-induced tumor eradication, as our TNC targeting MAREMO peptide reduced tumor cell numbers and plasticity upon IR.

Fields of Study & Subjects

Cell Adhesion Molecules Research Proteoglycans and glycosaminoglycans research Cellular Mechanics and Interactions

Publication details

Journal / source
EMBO Molecular Medicine
Publisher
Springer Science and Business Media LLC
Volume
18
Issue
5
Pages
1707–1743
Publication date
31 March 2026
Language
EN